Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 128 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

The elucidation of species-specific receptor pharmacology: a case study using subtype selective para- and meta-carborane estrogen receptor agonists.
Adeluola AA, Radomska HS, Wilson TA, Kulp SK, Kabat A, Helms TH, Mayo AK, Montgomery EJ, Thomas J, Marcho LM, Costa T, Fukuda M, Kang DD, Vibhute S, Wang D, Bennett CE, Coss CC
J Pharmacol Exp Ther, JPET-AR-2023-001874, 27 Jun 2024
Cited by: 0 articles | PMID: 38936980
Add to export list
Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.
Guo Y, Remaily BC, Thomas J, Kim K, Kulp SK, Mace TA, Ganesan LP, Owen DH, Coss CC, Phelps MA
Clin Cancer Res, 30(5):942-958, 01 Mar 2024
Cited by: 0 articles | PMID: 37921739 | PMCID: PMC10922515
Add to export list Review Free full text in Europe PMC
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.
Vu TT, Kim K, Manna M, Thomas J, Remaily BC, Montgomery EJ, Costa T, Granchie L, Xie Z, Guo Y, Chen M, Castillo AMM, Kulp SK, Mo X, Nimmagadda S, Gregorevic P, Owen DH, Ganesan LP, Mace TA, [...] Phelps MA
Pharmacol Res, 199:107048, 23 Dec 2023
Cited by: 1 article | PMID: 38145833 | PMCID: PMC10798214
Add to export list Free full text in Europe PMC
Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.
Kaweesa EN, Bazioli JM, Pierre HC, Lantvit DD, Kulp SK, Hill KL, Phelps MA, Coss CC, Fuchs JR, Pearce CJ, Oberlies NH, Burdette JE
Mol Pharm, 20(6):3049-3059, 08 May 2023
Cited by: 1 article | PMID: 37155928 | PMCID: PMC10405366
Add to export list Free full text in Europe PMC
The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.
Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, [...] Mace TA
Int J Mol Sci, 23(13):7066, 25 Jun 2022
Cited by: 4 articles | PMID: 35806069 | PMCID: PMC9266939
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, [...] Owen DH
Clin Lung Cancer, 23(4):345-355, 08 Jan 2022
Cited by: 16 articles | PMID: 35131184 | PMCID: PMC9149057
Add to export list Free full text in Europe PMC
Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks.
Helms TH, Mullins RD, Thomas-Ahner JM, Kulp SK, Campbell MJ, Lucas F, Schmidt N, LeMoine DM, Getaneh S, Xie Z, Phelps MA, Clinton SK, Coss CC
Sci Rep, 11(1):3646, 11 Feb 2021
Cited by: 5 articles | PMID: 33574348 | PMCID: PMC7878907
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.
Castillo AMM, Vu TT, Liva SG, Chen M, Xie Z, Thomas J, Remaily B, Guo Y, Subrayan UL, Costa T, Helms TH, Irby DJ, Kim K, Owen DH, Kulp SK, Mace TA, Phelps MA, Coss CC
JCSM Rapid Commun, 4(2):232-244, 09 Feb 2021
Cited by: 5 articles | PMID: 34514376 | PMCID: PMC8420755
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Tzung-Huei L, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, [...] Lapalombella R
Clin Cancer Res, 27(8):2352-2366, 04 Feb 2021
Cited by: 16 articles | PMID: 33542077 | PMCID: PMC8054771
Add to export list Free full text in Europe PMC
Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis.
Mukherjee D, DiVincenzo MJ, Torok M, Choueiry F, Kumar RJ, Deems A, Miller JL, Hinton A, Geraghty C, Maranon JA, Kulp SK, Coss C, Carson WE, Conwell DL, Hart PA, Cooperstone JL, Mace TA
Sci Rep, 10(1):21824, 11 Dec 2020
Cited by: 4 articles | PMID: 33311549 | PMCID: PMC7733503
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.
Xie Z, Chen M, Goswami S, Mani R, Wang D, Kulp SK, Coss CC, Schaaf LJ, Cui F, Byrd JC, Jennings RN, Schober KK, Freed C, Lewis S, Malbrue R, Muthusamy N, Bennett C, Kisseberth WC, Phelps MA
AAPS J, 22(4):92, 16 Jul 2020
Cited by: 3 articles | PMID: 32676788 | PMCID: PMC7814188
Add to export list Free full text in Europe PMC
Retraction: Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Chao MW, Chu PC, Chuang HC, Shen FH, Chou CC, Hsu EC, Himmel LE, Huang HL, Tu HJ, Kulp SK, Teng CM, Chen CS
Oncotarget, 11(12):1096, 24 Mar 2020
Cited by: 0 articles | PMID: 32256981 | PMCID: PMC7105163
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Correction: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells.
Huang HL, Wu HY, Chu PC, Lai IL, Huang PH, Kulp SK, Pan SL, Teng CM, Chen CS
Oncogenesis, 9(2):27, 26 Feb 2020
Cited by: 0 articles | PMID: 32102990 | PMCID: PMC7044224
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor.
Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, Kulp SK, Campbell M, Bekaii-Saab T, Phelps MA, Chen CS, Coss CC
EMBO Mol Med, 12(2):e9910, 13 Jan 2020
Cited by: 15 articles | PMID: 31930715 | PMCID: PMC7005646
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS
Clin Cancer Res, 25(9):2940, 01 May 2019
Cited by: 0 articles | PMID: 31043388
Add to export list
Editor's Note: From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors.
Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS
Cancer Res, 79(7):1716, 01 Apr 2019
Cited by: 0 articles | PMID: 30936080
Add to export list
Retraction: Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.
Chu PC, Kulp SK, Chen CS
Carcinogenesis, 40(2):e14, 01 Apr 2019
Cited by: 0 articles | PMID: 31034564 | PMCID: PMC6487680
Add to export list Free full text in Europe PMC
Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor.
Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS
Mol Cancer Ther, 18(4):869, 01 Apr 2019
Cited by: 0 articles | PMID: 30936413
Add to export list
Retraction: Corrigendum: Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.
Chu PC, Kulp SK, Chen CS
Carcinogenesis, 40(2):e15, 01 Apr 2019
Cited by: 0 articles | PMID: 31034566 | PMCID: PMC6487679
Add to export list Free full text in Europe PMC
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.
Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, Xie Z, Kulp SK, Coss CC, Phelps MA, Albers T, Lebedyeva IO, Liu K
Cancer Immunol Res, 7(3):414-427, 04 Jan 2019
Cited by: 33 articles | PMID: 30610059 | PMCID: PMC6397681
Add to export list Free full text in Europe PMC
Retraction of "Development of a Novel Class of Glucose Transporter Inhibitors".
Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS
J Med Chem, 61(11):5056, 18 May 2018
Cited by: 0 articles | PMID: 29772905 | PMCID: PMC6086342
Add to export list Free full text in Europe PMC
Retraction of "Development of Novel Adenosine Monophosphate-Activated Protein Kinase Activators".
Guh JH, Chang WL, Yang J, Lee SL, Wei S, Wang D, Kulp SK, Chen CS
J Med Chem, 61(11):5055, 18 May 2018
Cited by: 0 articles | PMID: 29772897 | PMCID: PMC6147139
Add to export list Free full text in Europe PMC
Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42
Tseng Y, Liva SG, Dauki AM, Sovic M, Henderson SE, Kuo Y, Benedict JA, Kulp SK, Campbell M, Bekaii-Saab T, Phelps MA, Chen C, Coss CC
bioRxiv, 06 Nov 2017
Cited by: 1 article | PPR: PPR23909
Add to export list Preprint
Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells.
Huang HL, Wu HY, Chu PC, Lai IL, Huang PH, Kulp SK, Pan SL, Teng CM, Chen CS
Oncogenesis, 6(7):e359, 10 Jul 2017
Cited by: 6 articles | PMID: 28692035 | PMCID: PMC5541713
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC, Huang PH, Kulp SK, Chen CS
Pharmacol Res, 117:370-376, 08 Jan 2017
Cited by: 5 articles | PMID: 28077300
Add to export list Review

1-25 of 128 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

**The elucidation of species-specific receptor pharmacology: a case study using subtype selective para- and meta-carborane estrogen receptor agonists**.

Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.

Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.

The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.

Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.

Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks.

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.

Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.

Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis.

Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.

Retraction: Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.

Correction: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells.

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor.

Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.

Editor's Note: From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors.

Retraction: Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.

Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor.

Retraction: Corrigendum: Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.

SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.

Retraction of "Development of a Novel Class of Glucose Transporter Inhibitors".

Retraction of "Development of Novel Adenosine Monophosphate-Activated Protein Kinase Activators".

Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42

Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells.

Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.

Partnerships & funding